DAVITA INC.DVA

DAVITA INC. Revenue Disclosure

10-KFiled Feb 11, 20263 min read
Revenue recognition and accounts receivable
The Company's revenues by segment and primary payor source were as follows:
Year ended December 31, 2025
U.S. dialysisOther - Ancillary servicesConsolidated
Patient service revenues:
Medicare and Medicare Advantage$6,740,392 $$6,740,392 
Medicaid and Managed Medicaid871,695 871,695 
Other government349,651 914,387 1,264,038 
Commercial3,806,596 385,423 4,192,019 
Other revenues:
Medicare and Medicare Advantage507,613 507,613 
Medicaid and Managed Medicaid2 2 
Commercial15,399 15,399 
Other(1)
24,610 99,462 124,072 
Eliminations of intersegment revenues(60,958)(11,203)(72,161)
Total$11,731,986 $1,911,083 $13,643,069 
    
Year ended December 31, 2024
U.S. dialysisOther - Ancillary servicesConsolidated
Patient service revenues:
Medicare and Medicare Advantage$6,374,882 $$6,374,882 
Medicaid and Managed Medicaid863,947 863,947 
Other government343,705 717,735 1,061,440 
Commercial3,783,827 248,026 4,031,853 
Other revenues:
Medicare and Medicare Advantage463,731 463,731 
Medicaid and Managed Medicaid740 740 
Commercial21,396 21,396 
Other(1)
24,356 58,862 83,218 
Eliminations of intersegment revenues(71,747)(13,910)(85,657)
Total$11,318,970 $1,496,580 $12,815,550 
Year ended December 31, 2023
U.S. dialysisOther - Ancillary servicesConsolidated
Patient service revenues:
Medicare and Medicare Advantage$6,100,183 $$6,100,183 
Medicaid and Managed Medicaid833,744 833,744 
Other government354,304 500,137 854,441 
Commercial3,623,516 251,279 3,874,795 
Other revenues:
Medicare and Medicare Advantage460,991 460,991 
Medicaid and Managed Medicaid1,733 1,733 
Commercial32,329 32,329 
Other(1)
25,251 52,754 78,005 
Eliminations of intersegment revenues(88,222)(7,852)(96,074)
Total$10,848,776 $1,291,371 $12,140,147 
(1)Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.
The majority of the Company's non-patient service revenues from Medicare and Medicare Advantage, Medicaid and Managed Medicaid, and commercial sources represent risk-based revenues earned by the Company's U.S. IKC business.
For its IKC business, the Company recognized revenues for performance obligations satisfied in previous years of $171,385, $116,336, and $94,361 during the years ended December 31, 2025, 2024 and 2023, respectively. The delay in recognition of these amounts resulted predominantly from measurement limitations and recognition constraints on both the Company's complex VBC contracts with health plans, as well as its government Comprehensive Kidney Care Contracting (CKCC) program. The Company's revenue recognition for its government CKCC program has certain constraints for plan year 2025. See Note 1 "Other revenues" for a description of the Company's accounting for these value-based care arrangements.
No single commercial payor accounted for more than 10% of consolidated revenues or consolidated accounts receivable for the periods presented in these consolidated financial statements or at their period-ends, respectively. International operations generate approximately 10% of total consolidated revenues.
Accounts receivable from Medicare, including Medicare Advantage plans, and Medicaid, including managed Medicaid plans, were approximately $881,191 and $768,536 as of December 31, 2025 and 2024, respectively. Approximately 18% and 23% of the Company’s U.S. dialysis accounts receivable balances as of December 31, 2025 and 2024, respectively, were more than six months old. Of these accounts receivable, there were no significant balances over one year old at December 31, 2025. The Company's accounts receivable are principally due from Medicare and Medicaid programs and commercial insurance plans.

Historical Timeline

Fiscal YearFiled
2025Feb 11, 2026Showing above
2024Feb 13, 2025
2023Feb 14, 2024
2022Feb 22, 2023
2021Feb 11, 2022
2020Feb 12, 2021
2019Feb 21, 2020
2018Feb 22, 2019

About Revenue Disclosures

Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.

Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.

Other Available Disclosures

Income TaxesEarnings Per ShareFair ValuePP&EGoodwill & IntangiblesLeasesSegmentsDebtCommitmentsNew Standards